key: cord-0900027-oyqptid3
authors: VanDruff, Rembrandt R.; Lee, J. Kayle
title: Blunt and penetrating chest trauma with concomitant COVID-19 infections: Two case reports
date: 2021-07-05
journal: Trauma Case Rep
DOI: 10.1016/j.tcr.2021.100507
sha: c7446b59e05a6a3526c65b40b33cf8c5e39e0bc9
doc_id: 900027
cord_uid: oyqptid3

BACKGROUND: We present two patients: one with a blunt and one with a penetrating chest trauma mechanism and both with concomitant COVID-19 infections. FINDINGS: The first patient is a 23 year old previously healthy male who presented to a Level 1 trauma center following a motor vehicle collision with blunt chest trauma and respiratory failure. The second patient is a 30 year old previously healthy male who presented to a Level 1 trauma center for a stab wound to the anterior chest with a right ventricular injury. Both patients were incidentally found to be COVID positive. We discuss the impact of COVID positivity on management considerations in these trauma patients. CONCLUSION: Concurrent COVID infection in trauma patients with respiratory failure after pulmonary trauma can obscure the cause of the respiratory failure. At the time of this writing, management of both is similar, COVID-specific therapeutic agents are being investigated, and steroids carry the best evidence. Superimposed bacterial co-infections should be treated. Although timing of tracheostomy is institution-specific, when indicated it is still performed. COVID infection is often associated with a hypercoagulable state in trauma patients who are already at higher thrombotic risk. In keeping with normal practice after hemorrhagic resuscitation in trauma patients, an early aggressive initiation of prophylactic anticoagulation continues to be prudent. The benefit of empiric therapeutic anticoagulation is not yet known.

The superimposed bacterial pneumonia was treated appropriately. In one review of over 3800 COVID-19 patients, 7% had a bacterial co-infection. 2 This percentage was less than in previous influenza pandemics and findings do not support the routine use of prophylactic antibiotics in the management of confirmed COVID-19 infection.

Tracheostomy is an aerosol-generating procedure and poses a risk to healthcare providers. As the authors of the 2020 Lancet consensus article on the subject note, tracheostomy placement in COVID patients may not always be beneficial. Patient selection should reflect weaning potential, and timing should reflect decreased infectivity and stability. Specifically, it may be safest for clinicians to wait until viral shedding has ceased, which favors a later tracheostomy than typically performed. 3 On the other hand, tracheostomy is known to be associated with improved ventilator weaning, which may be beneficial in a hospital system depleted of resources with continuous influx of COVID patients. There is still no clear consensus on when tracheostomy should be performed for COVID-related respiratory failure. We believed the benefits outweighed the risks in this otherwise healthy young patient whose respiratory illness were more consistent with trauma rather than COVID; the tracheostomy was placed in the usual timeline and he subsequently recovered enough to tolerate decannulation by the time of discharge.

The second case promotes discussion of the interplay between the coagulopathy of trauma and the coagulopathy of COVID-19 infection. The patient underwent repair of a ventricular injury and had no apparent involvement of COVID-related respiratory complications. However, the incidence of thrombotic complications in ICU patients with COVID-19 infections is considerably higher than the average ICU or trauma patient. Initial series from multiple countries J o u r n a l P r e -p r o o f Journal Pre-proof have cited overall thromboembolic burden ranging from 22% to 31%. 4, 5 Early autopsy reports reveal pathological evidence of pulmonary thrombotic phenomena. 6 Tang and colleagues reported that 71.4% of COVID non-survivors, and merely 0.6% of survivors, fulfilled criteria for disseminated intravascular coagulation during their hospital stay. 7 The management of the coagulopathy of trauma involves two phases: prevention of hemorrhage, then prevention of secondary thrombotic events. Of particular interest in trauma surgery in the era of COVID-19 is the question of whether to employ a more aggressive anticoagulation strategy to counter the apparent procoagulant effects of COVID-19. In non-COVID trauma patients, prophylactic anticoagulation is initiated as soon as hemorrhage control is achieved. In 

Dexamethasone in Hospitalized Patients with Covid-19

Co-infections in people with COVID-19: a systematic review and meta-analysis

Tracheostomy in the COVID-19 era: global and multidisciplinary guidance

Thrombotic events in SARS-CoV-2 patients: an urgent call for ultrasound screening

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Prevalence of venous thromboembolism in patients with